A phase II study of Perioperative FOLFOX4 plus Bevacizumab for initially unresectable Advanced Colorectal Cancer.

ABSTRACT: Interventions: FOLFOX4+Bevacizumab 5FU bolus: 400 mg/m2 d1,2 5FU infusion: 600 mg/m2/22h d1,2 Oxaliplatin: 85mg/m2 d1 l-LV: 100mg/m2 d1,2 bevacizumab: 5mg/kg d1 Bevacizumab 5mg/m2 d1 Q2w Primary outcome(s): Completion rate of neoadjuvant chemotherapy. Possibility of curative surgery. Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2621009 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR